Durvalumab

Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.

Supports calderasib plus pembrolizumab in PD‑L1 ≥1% newly diagnosed metastatic KRAS G12C NSCLC; positive Phase 1 KANDLELIT‑001 data; multiple Phase 3 trials planned; developed with Taiho/Astex